SfN 2022 - Page 1

Neurology/Psychiatric

Neuroanatomy analysis of new mouse models of autism

Dec. 2, 2022

Researchers from The Hospital for Sick Children have created mouse models related to autism. Nine novel models related to autism were produced in C57BL/6NCrl (B6N) mice using loss-of-function mouse lines with knockout of genes Katnal2, L2hgdh, Nexmif, Otc, Pah, Rab39b, Ranbp17, Upf3b and Ypel2.

Stroke illustration: brain, artery, neurons

Cardiovascular

SynB1-ELP-p50i NF-κB inhibitor peptide reduces infarct volume in MCAO model

Dec. 1, 2022

Ischemic stroke comprises about 87% of stroke incidence. The nuclear factor κ B (NF-κB) cascade is a major regulatory pathway of inflammation and is activated in response to ischemic stroke in humans and in rodents during middle cerebral artery occlusion (MCAO).

Neurology/Psychiatric

Researchers develop murine model of AD with late-onset cognitive impairment

Nov. 30, 2022

Alzheimer’s disease (AD) is still the most prevalent neurodegenerative disorder, with few FDA-approved treatments and many that have failed; further understanding of AD’s disease mechanisms is required. Investigators from Gempharmatech Inc. have developed a novel AD murine model (FAD4T) in which APP (Swedish and Indiana mutations) and PSEN1 M146L/L286V mutations were inserted into the mice’s genome.

Inflammatory

Novel TAK1 inhibitor alleviates inflammatory and neuropathic pain

Nov. 30, 2022

Researchers from Eydis Bio Inc. reported the discovery and preclinical characterization of a novel mitogen-activated protein kinase kinase kinase 7 (MAP3K7/TAK1) inhibitor, EYD-001, being developed for the treatment of inflammatory and neuropathic pain.

Endocrine/Metabolic

MYT-109, a promising treatment for Leigh syndrome

Nov. 29, 2022

Leigh syndrome is a rare neurometabolic disorder that causes the CNS to degenerate. Investigators from the University of California, Davis, and Myto Therapeutics Inc. noted that the NDUFS4-knockout (KO) mouse is a well-characterized model for this disease and shared results on the effects of monomethyl fumarate prodrug MYT-109 in this murine model.

Neurology/Psychiatric

Researchers develop tuberous sclerosis model in tsc2-mutant zebrafish

Nov. 28, 2022

Tuberous sclerosis is a genetic disease caused by loss-of-function mutations in the TSC1 or TSC2 genes. At the neurological level, this rare disease is characterized by benign tumor growth, epilepsy, cognitive deficits and autism. Epilepsy is the main neurological trait and presents mostly as infantile spasms.

Neurology/Psychiatric

Insulin signaling in brain cells tied to Alzheimer's disease pathology

Nov. 28, 2022

Brain insulin signaling is known to control peripheral energy metabolism and regulation of mood and cognition. Dysregulation in this signaling has been tied to brain pathological disorders such as Alzheimer’s disease (AD). Previous findings have reported a strong connection between type 2 diabetes (T2D) and AD, suggesting insulin resistance as a potential risk factor for AD pathology and other forms of dementia.

Neurology/Psychiatric

SUVN-L1305022 demonstrates antipsychotic activity in vivo

Nov. 25, 2022

Researchers from Suven Life Sciences Ltd. presented the discovery and preclinical characterization of a novel muscarinic acetylcholine M4 receptor positive allosteric modulator (PAM), SUVN-L1305022.

Neurology/Psychiatric

ATH-1018 and ATH-1020 ameliorate diabetic neuropathic pain in rats

Nov. 25, 2022

Neuropathic pain affects about 60% of patients with diabetes. The hepatocyte growth factor (HGF)/MET pathway is known to play a critical role in neurogenesis and nervous system repair; thus, its stimulation may provide neuroprotective effects, as well as reduce pain symptoms.

Hands illustrating pain and inflammation

Neurology/Psychiatric

Acute intermittent hypoxia improves nerve repair in nerve compression and decompression model

Nov. 23, 2022

Researchers presented data from a study that aimed to assess the repair potential of acute intermittent hypoxia (AIH) treatment for compression injuries.